The approval process for biosimilar erythropoiesis-stimulating agents
about
History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?Development and 10-year history of a biosimilar: the example of Binocrit®.
P2860
The approval process for biosimilar erythropoiesis-stimulating agents
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The approval process for biosimilar erythropoiesis-stimulating agents
@ast
The approval process for biosimilar erythropoiesis-stimulating agents
@en
The approval process for biosimilar erythropoiesis-stimulating agents
@nl
type
label
The approval process for biosimilar erythropoiesis-stimulating agents
@ast
The approval process for biosimilar erythropoiesis-stimulating agents
@en
The approval process for biosimilar erythropoiesis-stimulating agents
@nl
prefLabel
The approval process for biosimilar erythropoiesis-stimulating agents
@ast
The approval process for biosimilar erythropoiesis-stimulating agents
@en
The approval process for biosimilar erythropoiesis-stimulating agents
@nl
P2860
P356
P1476
The approval process for biosimilar erythropoiesis-stimulating agents
@en
P2093
Jay B Wish
P2860
P304
P356
10.2215/CJN.01770214
P407
P577
2014-06-26T00:00:00Z